Since 2024, I have served as a Principal Scientist in Toxicology at Pioneering Medicines (Flagship Pioneering), where I lead toxicology strategy and provide expert guidance from discovery through IND-enabling development across a diverse portfolio that includes small molecules, biologics, RNA, gene, and cell therapies. I drive nonclinical safety strategy, design and oversee non-GLP and GLP studies, and conduct comprehensive target and chemical risk assessments. I implement in silico and in vitro screening approaches for early de-risking, manage CRO partnerships and contracts, and author regulatory submissions including INDs and IMPDs. I also develop translational safety biomarker strategies, integrate mechanistic insights to enhance clinical relevance, and collaborate across functions to guide program decisions, while upholding scientific rigor and mentoring within a dynamic, innovation-driven environment.